Moderate Established

描述

Ciprofloxacin consistently enhances warfarin's anticoagulant effect, raising INR and increasing the risk of bleeding complications.

机制

Ciprofloxacin inhibits CYP1A2, reducing the metabolism of R-warfarin; it also suppresses gut flora, diminishing intestinal vitamin K production.

临床意义

Clinically significant INR elevations occur in a substantial proportion of patients; GI and urinary tract bleeding have been documented.

处理措施

Check INR 3–5 days after starting ciprofloxacin and after completing the course; reduce warfarin dose empirically by ~10–15% if INR trending up.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.